Neuronetics stock (US63009R1005): earnings move puts focus back on growth outlook

Neuronetics has reported fresh quarterly figures and updated its outlook, putting the focus back on growth, profitability and demand for its NeuroStar TMS system. What the latest numbers reveal – and which questions remain for investors.

Neuronetics reported new quarterly results in early May 2026, including revenue trends and an updated outlook for its NeuroStar transcranial magnetic stimulation (TMS) depression treatment business, according to a company earnings release published in May 2026 on its investor relations site and subsequent coverage from financial news outlets such as Neuronetics IR as of 05/2026 and market data services referenced by major US exchanges. The numbers highlighted continued focus on procedure growth, capital system placements and operating efficiency.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Neuronetics Inc
• Sector/industry: Medical technology / mental health
• Headquarters/country: United States
• Core markets: Depression treatment practices and psychiatric clinics, mainly in the US
• Key revenue drivers: NeuroStar TMS system sales and treatment session revenues
• Home exchange/listing venue: Nasdaq (ticker: STIM)
• Trading currency: US dollar (USD)

Neuronetics: core business model

Neuronetics is a US-based medical technology company focused on non-invasive neuromodulation for mental health, especially major depressive disorder (MDD). Its flagship product is the NeuroStar TMS system, a device that delivers targeted magnetic pulses to specific brain regions. The company generates revenue by selling capital equipment to practices and by recurring usage-based income linked to treatment sessions, as described in its corporate overview and filings on the investor site Neuronetics IR as of 03/2026.

In the US, TMS has become an established option for patients with treatment-resistant depression, complementing medication and psychotherapy. Neuronetics positions NeuroStar as a platform that integrates with psychiatric and behavioral health workflows, aiming to help practices expand their service offerings while improving patient outcomes. The business model therefore combines medical device economics with a recurring, procedure-driven revenue structure.

The company’s strategy emphasizes growing the installed base of NeuroStar systems in clinics, increasing utilization of each system through higher treatment volumes and follow-up courses, and supporting practices via marketing, training and practice development services. This mix of hardware, consumables and practice support is designed to create long-term customer relationships and recurring revenue, a point the management team has highlighted across recent earnings presentations, according to prepared remarks released alongside results on Neuronetics IR as of 05/2026.

Main revenue and product drivers for Neuronetics

The main revenue driver for Neuronetics is the NeuroStar Advanced Therapy system, which is installed in outpatient psychiatric practices, hospital-affiliated clinics and specialty mental health centers. Revenue streams include the initial sale or placement of the TMS equipment and recurring revenue from treatment session tokens or similar usage-based products that are required for each course of therapy. The company’s filings indicate that recurring revenues form a substantial portion of total sales, creating visibility as practices build patient volumes.

Reimbursement plays a critical role. In the US, commercial insurers and Medicare cover TMS treatment for certain depression indications under specific criteria. Changes in coverage policies, coding and reimbursement rates can influence procedure volumes and practice economics. Neuronetics regularly points to payer coverage expansion and coding stability as key supports for demand, according to management commentary summarized in its quarterly results documentation on Neuronetics IR as of 11/2025.

Beyond depression, Neuronetics has also explored or discussed additional indications and clinical research areas within neuromodulation. These may include other psychiatric or neurological conditions where TMS could be beneficial. While such programs are at different stages of development, they represent potential longer-term growth drivers if supported by clinical data and regulatory decisions. For now, however, major depressive disorder remains the central commercial focus for NeuroStar and the main contributor to current financial results.

Conclusion

Neuronetics remains a specialized player in the US mental health technology space, with its NeuroStar TMS system at the center of its business model and financial performance. Recent quarterly results have refocused attention on the balance between growth and progress toward profitability, as management works to expand the installed base while driving utilization and optimizing costs. For US investors, the stock offers exposure to the intersection of medical technology and behavioral health, an area influenced by reimbursement trends, clinical adoption and competitive dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.